Fabior Foam, 0.1% Approved for Acne Vulgaris - Monthly Prescribing Reference

Fabior contains tazarotene, a retinoid in a topical foam formulation. While the mechanism of action is not clearly defined, the therapeutic effect of tazarotene in acne may be due to its anti-hyperproliferative, normalizing-of-differentiation and anti ...

Stiefel receives US FDA approval of Fabior™ Foam, 0.1% - Yahoo Finance

RESEARCH TRIANGLE PARK, N.C., May 11, 2012 /PRNewswire/ -- Stiefel, a GSK (GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%. It is the only retinoid ...

Stiefel Gets FDA Approval Of Fabior Foam, 0.1% - NASDAQ

(RTTNews.com) - Stiefel, a GlaxoSmithKline plc (GSK, GSK.L) company, said Friday that the US Food and Drug Administration has approved the New Drug Application for Fabior, or tazarotene, Foam, 0.1%. It is the only retinoid in a topical foam ...

US FDA approves Stiefel's Fabior Foam, 0.1% to treat acne - pharmabiz.com

The US Food and Drug Administration has approved Stiefel's, a GSK company, New Drug Application for Fabior (tazarotene) Foam, 0.1 per cent. It is the only retinoid in a topical foam formulation for the treatment of acne vulgaris in patients 12 years of age ...

Glaxo's Acne Drug Gets U.S. Nod - Analyst Blog - Boston Globe

GlaxoSmithKline (GSK) recently announced that its subsidiary Stiefel’s Fabior (tazarotene) Foam, 0.1%, received approval from the U.S. Food and Drug Administration (FDA). Fabior Foam, 0.1% is approved as a topical treatment for acne vulgaris ...

FDA approves GSK topical acne treatment - SmartBrief

Want to see more news summaries? Sign up for AHIP Solutions SmartBrief AHIP Solutions SmartBrief is a FREE, daily email newsletter that summarizes the day's top industry news from hundreds of sources. Each day, subscribers receive 8-10 headlines and news ...

Stiefel receives US FDA approval of Fabior(tm) Foam, 0.1% - Stockhouse

RESEARCH TRIANGLE PARK, N.C., May 11, 2012 /PRNewswire/ -- Stiefel, a GSK (NYSE: GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%. It is the only retinoid in a ...

FDA approves GSK's topical acne treatment Fabior - SmartBrief

GlaxoSmithKline received FDA approval to market Fabior, or tazarotene foam, a retinoid for those age 12 and older with acne vulgaris. The foam is contraindicated in pregnancy and might harm the fetus, the company said.

Stiefel receives U.S. FDA approval of Fabior foam, 0.1% - Yahoo Finance

Stiefel, a GSK company announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%. It is the only retinoid in a topical foam formulation for the treatment of acne vulgaris in ...